Microbot Medical ( (MBOT) ) has shared an update.
Microbot Medical Inc. has announced a surge in patient enrollment for its ACCESS-PVI clinical trial, evaluating the LIBERTY® Endovascular Robotic Surgical System, which may lead to an earlier completion than expected. With 80% of participants finished with follow-up, the company is on schedule for a 510(k) submission to the FDA by the end of 2024. Additionally, all required biocompatibility tests have been successfully completed, and the FDA has granted full approval for the study.
For a thorough assessment of MBOT stock, go to TipRanks’ Stock Analysis page.
